IBEX Limited called its 2025 annual meeting for December 5, 2025 via virtual webcast to vote on five proposals, including electing eight directors, authorizing the Board to fill vacancies, approving an Amended & Restated 2020 Long‑Term Incentive Plan (A&R 2020 LTIP), and appointing Deloitte & Touche LLP as auditor with Audit Committee authority to set fees. The record date is October 10, 2025.
The A&R 2020 LTIP would add 650,000 Common Shares, bringing the plan’s aggregate share reserve to 2,637,326.13 shares, reset the term through December 5, 2035, set a non‑employee director annual compensation limit of $450,000 (or $900,000 in the first year), prohibit dividends on unvested awards, add double‑trigger acceleration following a change in control, and prohibit option/SAR repricing without shareholder approval.
IBEX notes it is no longer a Nasdaq “controlled company” (effective November 19, 2024) and reports five independent directors out of eight. Committee activity, director attendance, and updated non‑employee director compensation (including RSU grants to new directors) are detailed. The Board recommends voting “FOR” all proposals.
IBEX Ltd filed a Form 3 under Section 16(a) for its Chief Technology Officer. The filing states that no securities are beneficially owned by the reporting person. The stated event date is 10/01/2025. The form was executed by Lisa Lenstrohm as attorney-in-fact, with an attached Exhibit 24 power of attorney.
The filer submitted a Form 144 for IBEX Ltd showing a proposed sale of 1,275 common shares to be executed via NASDAQ with an aggregate market value of $50,466.87 and an approximate sale date of 10/02/2025. The shares were acquired on 09/30/2025 by the vesting of a performance grant totaling 4,196 shares. The filing records prior sales by the same person of 438 shares for $12,732.51 on 08/26/2025 and 2,295 shares for $93,475.69 on 09/19/2025. The notice identifies the broker as Global Shares Financial Services Inc. and reports total shares outstanding of 13,315,077. The signer certifies no undisclosed material adverse information.
IBEX Ltd filed a Form 144 reporting a proposed sale of 6,711 common shares with an aggregate market value of $265,632.78, expected to occur on 10/02/2025 on NASDAQ. The shares were acquired by vesting of a performance grant on 09/30/2025 totaling 14,524 shares. The filing also discloses two recent sales by the same account: 1,634 shares sold on 08/26/2025 for $47,544.08 and 45,027 shares sold on 09/16/2025 for $1,751,100.03. The filer attests there is no undisclosed material adverse information.
IBEX Ltd filed a Form 144 notifying a proposed sale of 697 common shares with an aggregate market value of $27,587.95, scheduled approximately for 10/02/2025. The filing shows 13,315,077 shares outstanding for the issuer and states the 697 shares were acquired on 09/30/2025 by vesting of a performance grant (2,347 shares noted as granted and vested on that date).
The filing also discloses prior sales by Paul Joseph Inson within the past three months: 10,000 shares on 08/22/2025 for $300,013.00, 255 shares on 08/26/2025 for $7,428.15, and 3,831 shares on 09/12/2025 for $149,179.14. The filer certifies no undisclosed material adverse information is known.
IBEX Ltd insider Christina Alice Trofimuk-O'Connor filed a Form 144 to sell 1,001 shares of common stock on NASDAQ with an aggregate market value of $39,621.33 and an approximate sale date of 10/02/2025. The filing states these shares were acquired by the filer on 09/30/2025 through the vesting of a performance grant totaling 3,228 shares and shows recent open-market disposals of 366 shares on 08/26/2025 for $10,661.58 and 844 shares on 09/16/2025 for $32,494.00. The filing includes the standard representation that the filer is not aware of undisclosed material adverse information about the issuer.
On 09/30/2025 IBEX Ltd director and Chief People Officer Paul Joseph Inson had 2,347 performance-based stock units (PSUs) certified for the period ending 06/30/2025 and converted into 2,347 common shares. To satisfy tax withholding from that vesting, the reporting person sold 697 shares on 10/02/2025 at a weighted average price of $39.581, executed in multiple trades priced between $39.34 and $40.01. After these transactions the reporting person beneficially owned 4,916 common shares. The Form 4 states the sale was required to cover tax obligations and not a discretionary trade.
Christina Alice Trofimuk-O'Connor, Chief Legal Officer of IBEX Ltd (IBEX), had 3,228 performance-based stock units (PSUs) vest and convert into common shares on 09/30/2025. To satisfy tax-withholding obligations tied to that vesting, she sold 1,001 shares on 10/02/2025 at a weighted-average price of $39.5817, leaving her with 13,954 shares beneficially owned. The Form 4 states the PSUs were earned after certification of performance for the period ending 06/30/2025, and the reported sale was not a discretionary trade but a tax-withholding sale.
On September 30, 2025 IBEX Ltd director and Chief Sales and CS Officer Bruce Neil Dawson had 3,228 performance-based stock units (PSUs) certified as earned for the period ending June 30, 2025 and converted to common shares, bringing his total ownership to 7,720 shares following that acquisition. A subsequent sale on October 2, 2025 disposed of 959 shares at a weighted-average price of $39.5824, reducing his direct holdings to 6,761 shares.
The Form 4 states the 3,228 shares were acquired on vesting of performance awards and the 959 shares were sold solely to satisfy tax withholding obligations, not as discretionary trades. The filing discloses the sales executed in multiple trades at prices between $39.34 and $40.01.